Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.55 |
| ▸ | SRC | P12931 | 9/20 | 0.55 |
| ▸ | GSK3A | P49840 | 8/20 | 0.55 |
| ▸ | SYK | P43405 | 7/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.55 |
| ▸ | HCK | P08631 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656468 | 0.89 | MAPK14 (0.47) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL28705005 | 0.85 | MAPK14 (0.51) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL13504234 | 0.85 | KDR (0.47) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL13331029 | 0.84 | GCK (0.49) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL12158272 | 0.84 | HCK (0.55) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL2561277 | 0.84 | SMN1; SMN2 (0.53) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL2554803 | 0.84 | GCK (0.65) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL12281768 | 0.83 | MAPK14 (0.43) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL28708295 | 0.83 | GCK (0.45) | MAPK14SRCGSK3ASYKMAPK12 | |
| SCHEMBL14656316 | 0.83 | MAPK14 (0.44) | MAPK14SRCGSK3ASYKMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| EP-2890460-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20120136031-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LTD. (GB) | 2012-05-31 | — | — | US | disclosed |
| EP-2414347-A1 | P38MAP KINASE INHIBITOR | Respivert Limited (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK14 25/4885SRC 634/4885GSK3A 165/4885 |
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | MAPK14 4207/4885SRC 3928/4885GSK3A 3153/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | MAPK14 31/4885SRC 872/4885GSK3A 990/4885 |
| US-20120136031-A1 | P38MAP KINASE INHIBITOR | MAPK1, MAP3K1, MAP3K11 | MAPK14 17/4885SRC 338/4885GSK3A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.